在因假体周围关节感染行翻修全髋关节置换术中,小梁金属髋臼部件是否降低再翻修风险?基于NJR数据集的研究
基于英格兰和威尔士国家关节注册中心(NJR)数据的回顾性观察研究,纳入因假体周围关节感染(PJI)行翻修全髋关节置换术且使用同一制造商非骨水泥髋臼部件的794例,其中小梁金属(TM)组541例、非TM组253例。Fine-Gray回归分析显示,两组5年髋臼部件累及生存率及无感染植入物生存率均无显著差异,作者建议对TM部件防感染的近期主张持谨慎态度。
要点
- 因PJI行翻修THA时,TM与非TM髋臼部件的5年髋臼部件生存率无显著差异(亚风险比0.78,95%CI 0.37-1.65,p=0.509)。
- 因PJI行翻修THA时,TM与非TM髋臼部件的5年无感染植入物生存率无显著差异(亚风险比0.97,95%CI 0.48-1.96,p=0.942)。
- 作者建议对TM部件可能预防感染的近期主张持谨慎态度。
核心结论
- 未发现证据支持因PJI翻修时使用TM髋臼部件较同一制造商非TM植入物可降低后续全因再翻修或感染再翻修风险,作者建议对TM部件可能防感染的近期主张持谨慎态度。
研究设计与样本
- 回顾性观察研究,使用英格兰和威尔士NJR数据,该注册中心患者同意率92%、可链接手术率94%。
- 全因翻修11,988例中,794例因PJI翻修且使用同一制造商非骨水泥髋臼部件,TM组541例、非TM组253例。
- 两组基线在性别、年龄、体质指数和ASA分级方面可比。
- 采用Fine-Gray回归分析考虑竞争死亡风险,模型按倾向评分校正(年龄、性别、ASA分级、术者级别、入路和翻修手术类型)。
主要发现
- 5年髋臼部件累积生存率TM组96.3%(95%CI 94%-98%)vs 非TM组94.4%(95%CI 90%-97%),亚风险比0.78(95%CI 0.37-1.65,p=0.509),无显著差异。
- 5年无感染植入物累积生存率TM组94.8%(95%CI 92%-97%)vs 非TM组94.4%(95%CI 90%-97%),亚风险比0.97(95%CI 0.48-1.96,p=0.942),无显著差异。
临床怎么用
- 作者建议对TM部件可能预防感染的近期主张持谨慎态度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A single-center study of 144 THAs revised specifically for periprosthetic joint infection (PJI) observed that trabecular metal (TM) acetabular components had a reduced risk of rerevision for subsequent infection compared with non-TM implants. It was suggested that TM was protective against infection after revision and that TM may be useful when revising THAs for PJI. Three registry studies have subsequently assessed the effect of TM on future infection. In the National Joint Registry (NJR) for England and Wales, we earlier reported lower revision rates for infection when TM (versus non-TM) was used in primary THA, but no difference in rerevision rates for infection when TM was used for all-cause revision THAs. The latter findings in all-cause revisions were also confirmed in a study from the Swedish and Australian registries. It is possible that TM only reduces the risk of infection when it is specifically used for PJI revisions (rather than all-causes). However, to date, the registry analyses have not had large enough cohorts of such cases to assess this meaningfully. QUESTIONS/PURPOSES: (1) In revision THAs performed for PJI, are rerevision rates for all-cause acetabular indications lower with TM acetabular components compared with non-TM designs? (2) In revision THAs performed for PJI, are rerevision rates of any component for infection lower with TM acetabular components compared with non-TM designs? METHODS: A retrospective observational study was performed using NJR data from England and Wales, which is the world's largest arthroplasty registry and contains details of over two million joint replacement procedures. The registry achieves high levels of patient consent (92%) and linked procedures (ability to link serial procedures performed on the same patient and hip; 94%). Furthermore, recent validation studies have demonstrated that when revision procedures have been captured within the NJR, the data completion and accuracy were excellent. Of 11,988 revisions performed for all causes, 794 were performed for PJI in which the same cementless acetabular component produced by one manufacturer was used. Acetabular components were either TM (n = 541) or non-TM (n = 253). At baseline the two groups were comparable for sex, age, body mass index, and American Society of Anesthesiologists (ASA) grade. Outcomes after revision THA (rerevision for all-cause acetabular indications and rerevision of any component for infection) were compared between the groups using Fine and Gray regression analysis, which considers the competing mortality risk. Regression models were adjusted for the propensity score, with this score summarizing many of the potential patient and surgical confounding factors (age, sex, ASA grade, surgeon grade, approach, and type of revision procedure performed). RESULTS: There was no difference in 5-year cumulative acetabular component survival rates between TM (96.3%; 95% confidence interval [CI], 94%-98%) and non-TM components (94.4%, 95% CI, 90%-97%; subhazard ratio, 0.78, 95% CI, 0.37-1.65; p = 0.509). There was no difference in 5-year cumulative implant survival rates free from infection between TM (94.8%; 95% CI, 92%-97%) and non-TM components (94.4%, 95% CI, 90%-97%; subhazard ratio, 0.97, 95% CI, 0.48-1.96; p = 0.942). CONCLUSIONS: We found no evidence to support the notion that TM acetabular components used for PJI revisions reduced the subsequent risk of all-cause rerevision or the risk of rerevision for infection compared with non-TM implants from the same manufacturer. We therefore advise caution against recent claims that TM components may protect against infection. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Matharu GS, Judge A, Murray DW, et al. Do Trabecular Metal Acetabular Components Reduce the Risk of Rerevision After Revision THA Performed for Periprosthetic Joint Infection? A Study Using the NJR Data Set. Clin Orthop Relat Res. 2019. PMID: 31136438. doi:10.1097/CORR.0000000000000570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。